12 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $5M | -$2M | 36.2% | -51.5% | -$5M | — | $259000 |
| 2024 | $5M | -$7M | 41.3% | -72.3% | -$10M | — | $4M |
| 2023 | $4M | -$14M | 51.2% | -137.0% | -$15M | — | $7M |
| 2022 | $7M | -$15M | 17.8% | -188.8% | -$14M | — | $21M |
| 2021 | $7M | -$15M | -28.4% | -524.0% | -$27M | $0 | $29M |
| 2020 | $8M | -$5M | 35.3% | -159.0% | -$33M | $2M | $14M |
| 2019 | $1M | -$29M | 0.0% | -1657.9% | -$19M | $107000 | $8M |
| 2018 | $1M | -$13M | 0.0% | -1152.3% | -$14M | $0 | $12M |
| 2017 | $4M | -$16M | 0.0% | -355.6% | -$14M | $0 | $9M |
| 2016 | — | -$20M | — | — | — | $25M | $2M |
| 2015 | — | -$18M | — | — | — | $25M | $24M |
| 2014 | — | -$18M | — | — | — | $10M | $17M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $1M | -$4M | 36.4% | -70.8% | — | — | $954000 |
| Dec '25 | $901000 | -$1M | 21.3% | -152.6% | -$861000 | — | $259000 |
| Sep '25 | $1M | $856000 | 32.1% | -88.5% | -$257000 | — | $1M |
| Jun '25 | $1M | -$4M | 43.4% | -34.4% | -$2M | — | $1M |
| Mar '25 | $1M | $3M | 43.2% | 44.2% | -$2M | — | $3M |
| Dec '24 | $1M | -$4M | 32.0% | -187.4% | -$2M | — | $4M |
| Sep '24 | $2M | -$2M | 32.9% | -114.5% | -$2M | — | $4M |
| Jun '24 | $1M | $1M | 51.5% | 151.6% | -$2M | — | $6M |
| Mar '24 | $987000 | -$2M | 52.3% | -160.9% | -$3M | — | $3M |
| Dec '23 | $777000 | -$3M | 77.1% | -153.5% | $26M | — | $7M |
| Sep '23 | $1M | -$3M | 37.0% | -107.6% | -$3M | — | $11M |
| Jun '23 | $1M | $823000 | 49.9% | -112.1% | -$5M | — | $13M |
| Mar '23 | $1M | -$9M | 44.2% | -313.9% | -$3M | — | $23M |
| Dec '22 | $744000 | -$4M | -21.0% | -626.1% | -$2M | — | $21M |
| Sep '22 | $2M | -$3M | 28.2% | -254.2% | -$3M | — | $23M |
| Jun '22 | $4M | -$4M | 10.7% | -98.1% | -$3M | — | $21M |
| Mar '22 | $3M | -$4M | -7.4% | -143.6% | -$5M | — | $25M |
| Dec '21 | $2M | -$9M | -72.9% | -635.8% | -$7M | $0 | $29M |
| Sep '21 | $2M | -$2M | -5.7% | -366.7% | -$8M | $114000 | $36M |
| Jun '21 | $1M | -$5M | -13.0% | -546.8% | -$6M | $1M | $44M |
How the market has priced RKDA against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Arcadia Biosciences, Inc.'s revenue has declined 9.6% per year. These are computed facts, not advice.
As of FY2025, Arcadia Biosciences, Inc. reported — of total debt against $259000 of cash.
In FY2025, gross margin was 36.2%, operating margin -51.5%, and net margin -48.1%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.